






Imatinib in the Early Chronic Phase

Richard Larson





Management of Chronic Myeloid Leukemia in Early Chronic Phase with Imatinib Mesylate (Glivec; Gleevec)



Richard A. Larson, M.D.
The University of Chicago

The IRIS Study: International Randomized Study of Interferon + Ara-C vs STI571* in Chronic Myeloid Leukemia

*Imatinib / Glivec / Gleevec

O'Brien et al. New England J Medicine March 13, 2003

Hahn et al. J Clin Oncol June 1, 2003

Hughes et al. New England J Medicine October 9, 2003

Druker et al. 5 Year update, in preparation

Patient characteristics


1106 early chronic phase CML patients,
enrolled from July 2000 – January 2001

Median time from Diagnosis 2 months

Age (median) 51 years

<u>Sokal risk group</u>	<u>Median Age</u>
Low (n=391)	46
Intermediate (n=228)	52
High (n=158)	51
Unknown (n=329)	49

Study Design, Current Patient Status, and Mean Follow-up (through Dec 2005)




Reasons for Cross-over

Lack of response	18%
Loss of response / increase in WBC	14%
Intolerance of treatment	26%
Reluctance to continue IFN	7%


Current Daily Dose of Imatinib for the 397 Patients Still on First-line Imatinib

- 300 mg 9%
 - 400 mg 81%
 - 600 mg 6%
 - 800 mg 4%
-
- Mean daily dose over entire treatment course is 382 +/- 50 mg.


Cumulative Best Response at 12 and 54 months on First-line Imatinib




Event-free Survival and Survival Without AP/BC on First-line Imatinib



Survival Without AP/BC by level of CyR at 12 months on First-line Imatinib



Survival Without AP/BC by Molecular Response at 12 months on First-line Imatinib




Annual Progression Events on First-line Imatinib (minimum of 4 years of follow-up)

<u>Year</u>	<u>Events*</u>	<u>AP/BC</u>
1st	3.4%	1.5%
2nd	7.5%	2.8%
3rd	4.8%	1.6%
4th	1.5%	0.9%

* All deaths plus loss of response **including** AP/BC

Estimated Log reduction of *BCR-ABL* at 4 years by Sokal score (in %)



J Goldman et al,
ASH 2005

Grade 3-4 Toxicity to First-line Imatinib

Overall
toxicity
(n=551)

Onset after
36 months
(n=427)

Hematologic / Liver

% of patients

Neutropenia

16.7

2.3

Thrombocytopenia

9.8

1.2

Anemia

4.7

0.9

Elevated liver enzymes

5.2

0.2

Other drug-related AEs

16.5

2.6

EVOLVING CONCEPTS IN THE MANAGEMENT OF CHRONIC MYELOID LEUKEMIA



RECOMMENDATIONS FROM AN EXPERT PANEL ON BEHALF OF THE EUROPEAN LEUKEMIANET